GlassScriptPhysician profile
Richard Lehman
NPI 1851392377
$5,130.94
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,065 · 2020: $1,523 · 2021: $1,515 · 2022: $14.62 · 2023: $13.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $2,835.70 | 2019-2021 | |
| Arthrex, INC. | $737.00 | 2019 | |
| Zyla Life Sciences, INC. | $321.67 | 2019-2020 | |
| Horizon Therapeutics Plc | $305.12 | 2019-2021 | |
| Pacira Therapeutics, INC. | $286.58 | 2019-2021 | |
| Baxter Healthcare | $151.47 | 2019 | |
| Ferring Pharmaceuticals INC. | $109.52 | 2019-2022 | |
| Assertio Therapeutics, INC. | $83.22 | 2019-2020 | |
| Smith+Nephew, INC. | $72.73 | 2019-2020 | |
| Bioventus LLC | $52.98 | 2019 | |
| Stryker Corporation | $48.94 | 2021 | |
| Zimmer Biomet Holdings, INC. | $38.04 | 2019-2023 | Tapestry, Ventix |
| Depuy Synthes Sales INC. | $19.52 | 2019 | |
| Acerus Pharmaceuticals Corporation | $18.42 | 2021 | |
| Iroko Pharmaceuticals, LLC | $13.65 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $12.92 | 2019 | |
| Sentynl Therapeutics, INC. | $12.42 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.